The 2023 Endpoints 11; Regeneron’s gene editing ambitions; GSK’s research revamp; Ripple effect of Dana-Farber, Brigham breakup; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

While an…
Click here to view original post